Amphastar Pharmaceuticals (AMPH) investor relations material

Business Overview and Strategic Vision

• Operates a fully integrated business model with in-house development, manufacturing, and distribution, ensuring quality and compliance; vertical integration supports growth and investment in business development.

• Employs a dual-strategy growth model focused on pipeline development and strategic acquisitions, with a shift toward proprietary and biosimilar drugs.

• Diversified branded and complex generic portfolio with a strong commercial engine and proprietary pipeline.

• Management emphasizes high quality, efficiency, and technology, resulting in strong net income margins and consistent revenue growth from 2018 to 2025.

• Entered 2026 with momentum across branded, generics, and pipeline, supported by a robust balance sheet.

Financial Performance and Growth Drivers

• Annual revenue grew from $295M in 2018 to $720M in 2025, with adjusted net income margin peaking at 27.4% in 2024.

• EPS increased at a 24% CAGR from 2021 to 2025, driven by new product launches and portfolio diversification.

• Mid to high single-digit revenue growth targeted for 2026, with operating expenses rising due to R&D and temporary G&A increases from ERP implementation.

• Strong balance sheet with $600M debt and $300M cash; net leverage just over 2x, with capacity for further acquisitions.

• No significant seasonality or weather impact expected; certain products like Baqsimi and glucagon peak in Q3, Primatene Mist stronger in Q1 and Q4.

Product Portfolio and Key Launches

• Commercial capabilities have expanded globally, with BAQSIMI® now available in over 26 countries and expected peak annual sales of $250–$275 million.

• Primatene Mist continues to deliver high single to low double-digit growth, supported by physician sampling and increased marketing; small price increase planned in H2 2026.

• Multiple generic and biosimilar launches are planned, including AMP-015 (Teriparatide, launched Dec 2025), AMP-007 (Ipratropium Bromide, launch Q2 2026), and AMP-004 (Insulin Aspart, launch expected 2027).

• No generic competition expected for Primatene Mist due to economic and regulatory barriers.

• Iron Sucrose expected to stabilize at ~$10M annual sales; teriparatide is a smaller contributor.